https://scholars.lib.ntu.edu.tw/handle/123456789/517630
標題: | A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia | 作者: | Gubelin Harcha W. Barboza Mart?nez J. TSEN-FANG TSAI Katsuoka K. Kawashima M. Tsuboi R. Barnes A. Ferron-Brady G. Chetty D. |
公開日期: | 2014 | 出版社: | Mosby Inc. | 卷: | 70 | 期: | 3 | 起(迄)頁: | 489-498 | 來源出版物: | Journal of the American Academy of Dermatology | 摘要: | Background Dihydrotestosterone is the main androgen causative of androgenetic alopecia, a psychologically and physically harmful condition warranting medical treatment. Objective We sought to compare the efficacy and safety of dutasteride (type 1 and 2 5-alpha reductase inhibitor) with finasteride (type 2 5-alpha reductase inhibitor) and placebo in men with androgenetic alopecia. Methods Men aged 20 to 50 years with androgenetic alopecia were randomized to receive dutasteride (0.02, 0.1, or 0.5 mg/d), finasteride (1 mg/d), or placebo for 24 weeks. The primary end point was hair count (2.54-cm diameter) at week 24. Other assessments included hair count (1.13-cm diameter) and width, photographic assessments (investigators and panel), change in stage, and health outcomes. Results In total, 917 men were randomized. Hair count and width increased dose dependently with dutasteride. Dutasteride 0.5 mg significantly increased hair count and width in a 2.54-cm diameter and improved hair growth (frontal view; panel photographic assessment) at week 24 compared with finasteride (P =.003, P =.004, and P =.002, respectively) and placebo (all P <.001). The number and severity of adverse events were similar among treatment groups. Limitations The study was limited to 24 weeks. Conclusions Dutasteride increased hair growth and restoration in men with androgenetic alopecia and was relatively well tolerated. ? 2013 by the American Academy of Dermatology, Inc. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84894075744&doi=10.1016%2fj.jaad.2013.10.049&partnerID=40&md5=671d6e7273007ff855aa4361b37c2ebd https://scholars.lib.ntu.edu.tw/handle/123456789/517630 |
ISSN: | 0190-9622 | DOI: | 10.1016/j.jaad.2013.10.049 | SDG/關鍵字: | androstanolone; dutasteride; finasteride; placebo; abdominal pain; adult; allergic rhinitis; article; backache; breast disease; breast tenderness; controlled study; diarrhea; disease severity; dose response; double blind procedure; drug efficacy; drug safety; drug withdrawal; ejaculation disorder; erectile dysfunction; hair analysis; hair growth; headache; human; influenza; intention to treat analysis; libido disorder; major clinical study; male; male type alopecia; middle aged; pharyngitis; phase 3 clinical trial (topic); premature ejaculation; priority journal; randomized controlled trial; rhinopharyngitis; sexual dysfunction; sexuality; treatment outcome; upper abdominal pain; upper respiratory tract infection; young adult; 5-alpha reductase; 5-alpha reductase inhibitors; androgenetic alopecia; dutasteride; finasteride; male pattern baldness; male pattern hair loss; treatment; Adult; Alopecia; Azasteroids; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Finasteride; Follow-Up Studies; Hair; Humans; Male; Middle Aged; Patient Satisfaction; Reference Values; Time Factors; Treatment Outcome; Young Adult |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。